このページの翻訳は実験的なもので、現在開発中です。お待ちしております
uniQure マネジメント
マネジメント 基準チェック /24
uniQure'sの CEO はMatt Kapustaで、 Dec2016年に任命され、 の在任期間は 7.67年です。 の年間総報酬は$ 6.58Mで、 9.6%給与と90.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.67%を直接所有しており、その価値は$ 2.21M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と6.9年です。
主要情報
Matt Kapusta
最高経営責任者
US$6.6m
報酬総額
| CEO給与比率 | 9.6% |
| CEO在任期間 | 7.8yrs |
| CEOの所有権 | 0.7% |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 7.1yrs |
経営陣の近況
Recent updates
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Jul 09Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$285m |
| Mar 31 2024 | n/a | n/a | -US$297m |
| Dec 31 2023 | US$7m | US$635k | -US$308m |
| Sep 30 2023 | n/a | n/a | -US$228m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$6m | US$609k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$125m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$324m |
| Dec 31 2021 | US$5m | US$583k | US$330m |
| Sep 30 2021 | n/a | n/a | US$321m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | -US$139m |
| Dec 31 2020 | US$4m | US$585k | -US$125m |
| Sep 30 2020 | n/a | n/a | -US$166m |
| Jun 30 2020 | n/a | n/a | -US$136m |
| Mar 31 2020 | n/a | n/a | -US$124m |
| Dec 31 2019 | US$4m | US$548k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$105m |
| Jun 30 2019 | n/a | n/a | -US$103m |
| Mar 31 2019 | n/a | n/a | -US$92m |
| Dec 31 2018 | US$3m | US$502k | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$78m |
| Mar 31 2018 | n/a | n/a | -US$78m |
| Dec 31 2017 | US$4m | US$468k | -US$79m |
報酬と市場: Mattの 総報酬 ($USD 6.58M ) は、 US市場 ($USD 2.41M ) の同規模の企業の平均を上回っています。
報酬と収益: Mattの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Matt Kapusta (52 yo)
7.8yrs
在職期間
US$6,584,919
報酬
Mr. Matthew Craig Kapusta, also known as Matt, serves as Director of Genezen Laboratories, Inc. since July 2024. He served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until Septe...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 7.8yrs | US$6.58m | 0.67% $ 1.5m | |
| CFO, Principal Financial Officer & GM of Amsterdam Site | 3.3yrs | US$2.12m | 0.16% $ 350.5k | |
| Chief Business & Scientific Officer | less than a year | US$2.62m | 0.068% $ 153.5k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 1.4yrs | US$2.54m | 0.022% $ 50.4k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | no data | データなし | データなし | |
| Chief Technical Operations | less than a year | データなし | データなし | |
| Business Development Director | 16.3yrs | データなし | データなし | |
| Chief Corporate Affairs Officer | 2.6yrs | US$1.22m | データなし | |
| Chief Medical Officer | 1.3yrs | データなし | 0.24% $ 532.5k | |
| Vice President of Global Medical Affairs | no data | データなし | データなし |
2.0yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: QUREの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 9.8yrs | US$6.58m | 0.67% $ 1.5m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 10.2yrs | データなし | データなし | |
| Independent Non-Executive Director | 4.3yrs | US$412.46k | 0.033% $ 73.9k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Non-Executive Director | 8.3yrs | US$424.96k | 0.013% $ 30.0k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Non-Executive Director | 7.1yrs | US$412.46k | 0.049% $ 109.8k | |
| Independent Non-Executive Director | 7.1yrs | US$424.96k | 0.049% $ 109.7k | |
| Independent Chairman of the Board | 6.3yrs | US$444.96k | 0.042% $ 93.6k | |
| Non-Executive Director | 6yrs | US$404.96k | 0.091% $ 204.0k |
7.1yrs
平均在職期間
71yo
平均年齢
経験豊富なボード: QUREの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。